These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17296437)

  • 1. Identification of target antigens in specific immunotherapy for renal cell carcinoma.
    Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
    J Urol; 2007 Mar; 177(3):1157-62. PubMed ID: 17296437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.
    Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
    Int J Oncol; 2006 Dec; 29(6):1555-60. PubMed ID: 17088996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients.
    Itoh Y; Komohara Y; Komatsu N; Minami T; Saito K; Noguchi M; Itoh K; Harada M
    Oncol Rep; 2007 Nov; 18(5):1231-7. PubMed ID: 17914578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
    Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
    Cancer Res; 2001 Sep; 61(17):6459-66. PubMed ID: 11522641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma.
    Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    J Immunother; 2015 Sep; 38(7):285-91. PubMed ID: 26261892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the SART3 tumor rejection antigen in renal cell carcinoma.
    Kawagoe N; Shintaku I; Yutani S; Etoh H; Matuoka K; Noda S; Itoh K
    J Urol; 2000 Dec; 164(6):2090-5. PubMed ID: 11061933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma.
    Komohara Y; Harada M; Ishihara Y; Suekane S; Noguchi M; Yamada A; Matsuoka K; Itoh K
    Oncol Rep; 2007 Dec; 18(6):1463-8. PubMed ID: 17982631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
    Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24
    Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients.
    Ogata R; Matsueda S; Yao A; Noguchi M; Itoh K; Harada M
    Prostate; 2004 Sep; 60(4):273-81. PubMed ID: 15264237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.
    Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    Int Immunopharmacol; 2014 May; 20(1):59-65. PubMed ID: 24583149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides.
    Kawashima H; Obayashi A; Kawamura M; Masaki S; Tamada S; Iguchi T; Uchida J; Kuratsukuri K; Tanaka T; Nakatani T
    BJU Int; 2014 Feb; 113(2):320-32. PubMed ID: 24895689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.
    Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco MA; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    Int Immunopharmacol; 2015 May; 26(1):133-8. PubMed ID: 25819666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients.
    Harada M; Ishihara Y; Itoh K; Yamanaka R
    Oncol Rep; 2007 Mar; 17(3):629-36. PubMed ID: 17273744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer.
    Hayashi S; Kumai T; Matsuda Y; Aoki N; Sato K; Kimura S; Kitada M; Tateno M; Celis E; Kobayashi H
    J Transl Med; 2011 Nov; 9():191. PubMed ID: 22053850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma.
    Sato E; Torigoe T; Hirohashi Y; Kitamura H; Tanaka T; Honma I; Asanuma H; Harada K; Takasu H; Masumori N; Ito N; Hasegawa T; Tsukamoto T; Sato N
    Clin Cancer Res; 2008 Nov; 14(21):6916-23. PubMed ID: 18980986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognition but suppresses non-MHC-restricted effector cell activity.
    Schendel DJ; Falk CS; Nössner E; Maget B; Kressenstein S; Urlinger S; Tampé R; Gansbacher B
    Gene Ther; 2000 Jun; 7(11):950-9. PubMed ID: 10849555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells.
    Seliger B; Dressler SP; Massa C; Recktenwald CV; Altenberend F; Bukur J; Marincola FM; Wang E; Stevanovic S; Lichtenfels R
    Proteomics; 2011 Jun; 11(12):2528-41. PubMed ID: 21595034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.